JP2009515890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515890A5 JP2009515890A5 JP2008540227A JP2008540227A JP2009515890A5 JP 2009515890 A5 JP2009515890 A5 JP 2009515890A5 JP 2008540227 A JP2008540227 A JP 2008540227A JP 2008540227 A JP2008540227 A JP 2008540227A JP 2009515890 A5 JP2009515890 A5 JP 2009515890A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- guanidino
- amino
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 192
- -1 amino, amidino, guanidino, hydrazino Chemical group 0.000 claims 162
- 125000003545 alkoxy group Chemical group 0.000 claims 50
- 125000004663 dialkyl amino group Chemical group 0.000 claims 50
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 46
- 125000003282 alkyl amino group Chemical group 0.000 claims 45
- 229910052736 halogen Inorganic materials 0.000 claims 45
- 150000002367 halogens Chemical class 0.000 claims 45
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 32
- 229910052757 nitrogen Inorganic materials 0.000 claims 31
- 125000001424 substituent group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000004076 pyridyl group Chemical group 0.000 claims 20
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 239000001301 oxygen Substances 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 210000000130 stem cell Anatomy 0.000 claims 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 11
- 239000000651 prodrug Substances 0.000 claims 11
- 229940002612 prodrug Drugs 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052717 sulfur Chemical group 0.000 claims 11
- 239000011593 sulfur Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical class C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims 9
- 125000001624 naphthyl group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 150000004867 thiadiazoles Chemical class 0.000 claims 9
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical class C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims 9
- 150000003852 triazoles Chemical class 0.000 claims 9
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 8
- 150000004866 oxadiazoles Chemical class 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 5
- 125000002636 imidazolinyl group Chemical group 0.000 claims 5
- 125000002883 imidazolyl group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 206010043276 Teratoma Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000004113 cell culture Methods 0.000 claims 3
- 230000024245 cell differentiation Effects 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010026673 Malignant Pleural Effusion Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029387 trophoblastic neoplasm Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 102000016362 Catenins Human genes 0.000 claims 1
- 108010067316 Catenins Proteins 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 206010025538 Malignant ascites Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000003567 ascitic fluid Anatomy 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73465505P | 2005-11-08 | 2005-11-08 | |
| US60/734,655 | 2005-11-08 | ||
| PCT/US2006/043859 WO2007056593A2 (en) | 2005-11-08 | 2006-11-08 | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515890A JP2009515890A (ja) | 2009-04-16 |
| JP2009515890A5 true JP2009515890A5 (enExample) | 2009-12-24 |
| JP5536336B2 JP5536336B2 (ja) | 2014-07-02 |
Family
ID=37890190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540227A Active JP5536336B2 (ja) | 2005-11-08 | 2006-11-08 | α−ヘリックス類似体および癌幹細胞の治療に関する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20070129353A1 (enExample) |
| EP (1) | EP1957516B1 (enExample) |
| JP (1) | JP5536336B2 (enExample) |
| KR (1) | KR101486490B1 (enExample) |
| AU (1) | AU2006311433B2 (enExample) |
| CA (1) | CA2629136C (enExample) |
| ES (1) | ES2570994T3 (enExample) |
| WO (1) | WO2007056593A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7566711B2 (en) * | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US8080657B2 (en) * | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| US7232822B2 (en) | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7576084B2 (en) | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US20090215783A1 (en) * | 2006-05-30 | 2009-08-27 | Choongwae Pharma Corporation | Composition for induction or inhibition of stem cell differentiation |
| US20080118518A1 (en) * | 2006-09-07 | 2008-05-22 | Cirrito Thomas P | Cancer stem cell-targeted cancer therapy |
| AU2008325219A1 (en) * | 2007-11-05 | 2009-05-14 | Puretech Ventures | Methods, kits, and compositions for administering pharmaceutical compounds |
| JP5530427B2 (ja) | 2008-06-06 | 2014-06-25 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | アルファへリックスミメティック及び関連の方法 |
| WO2010001989A1 (ja) * | 2008-07-03 | 2010-01-07 | 協和発酵キリン株式会社 | 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤 |
| WO2010011864A2 (en) * | 2008-07-23 | 2010-01-28 | The Scripps Research Institute | Alpha-helix mimetic with functionalized pyridazine |
| CA2735177C (en) * | 2008-08-29 | 2014-03-25 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Saturated bicyclic heterocyclic derivatives as smo antagonists |
| US20100080855A1 (en) * | 2008-09-12 | 2010-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies |
| US8691819B2 (en) | 2008-10-14 | 2014-04-08 | Prism Biolab Corporation | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions |
| SG175045A1 (en) * | 2009-04-15 | 2011-11-28 | Jw Pharmaceutical Corp | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| WO2010128685A1 (en) * | 2009-05-07 | 2010-11-11 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| JPWO2011096440A1 (ja) | 2010-02-03 | 2013-06-10 | 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ | 天然変性タンパク質に結合する化合物およびそのスクリーニング方法 |
| BR112012030298A2 (pt) | 2010-05-28 | 2015-09-29 | Univ Texas | compostos de oligo-banzamida e seu uso |
| ES2552462T3 (es) | 2010-10-14 | 2015-11-30 | Jw Pharmaceutical Corporation | Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo |
| AU2011338530B2 (en) | 2010-12-06 | 2017-06-15 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
| WO2012115286A1 (en) | 2011-02-25 | 2012-08-30 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
| JP6124880B2 (ja) | 2011-06-09 | 2017-05-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多能性幹細胞の血管床細胞への分化のための方法 |
| WO2013078277A1 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
| WO2013078288A1 (en) * | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
| EP3057590B1 (en) | 2013-10-18 | 2019-11-27 | PRISM BioLab Co., Ltd. | Treatment of hepatic fibrosis using an inhibitor of cbp/catenin |
| ES2774790T3 (es) | 2014-03-28 | 2020-07-22 | Nat Univ Corp Tottori Univ | Efecto inhibidor de compuesto de bajo peso molecular en cáncer y fibrosis |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| GB201617630D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| CN112567022A (zh) | 2018-08-21 | 2021-03-26 | 豪夫迈·罗氏有限公司 | 用于评定跨内皮屏障完整性的方法 |
| CN112805370A (zh) | 2018-10-19 | 2021-05-14 | 豪夫迈·罗氏有限公司 | 诱导高阻力跨内皮屏障的协同转录因子 |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| US11639356B2 (en) | 2020-10-05 | 2023-05-02 | Genesis Molecular Technologies, Inc. | Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5929237A (en) * | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US6294525B1 (en) * | 1999-09-01 | 2001-09-25 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US7008941B2 (en) * | 2001-05-16 | 2006-03-07 | Myriad Genetics, Inc. | Reverse-turn mimetics and methods relating thereto |
| US7232822B2 (en) * | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7576084B2 (en) * | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7566711B2 (en) * | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7671054B1 (en) * | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| JP4387793B2 (ja) * | 2001-10-12 | 2009-12-24 | チョンウェ ファーマ コーポレーション | 逆向ターンミメティックおよびそれに関連した方法 |
| AU2003284120A1 (en) * | 2002-10-17 | 2004-05-04 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US7390814B2 (en) * | 2003-02-13 | 2008-06-24 | Sanofi-Aventis Deutschland Gmbh | Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments |
| KR20050111588A (ko) * | 2003-02-13 | 2005-11-25 | 사노피-아벤티스 도이칠란트 게엠베하 | 치환된 헥사하이드로피라지노[1,2-ａ]피리미딘-4,7-디온유도체, 이의 제조방법 및 약제로서의 이의 용도 |
| CN1871239A (zh) * | 2003-08-28 | 2006-11-29 | (株)中外制药 | β－联蛋白/TCF激活转录的调节 |
| WO2006101858A1 (en) * | 2005-03-18 | 2006-09-28 | Institute For Chemical Genomics | Alpha-helix mimetics and methods relating to the treatment of fibrosis |
| US7563825B1 (en) * | 2005-03-18 | 2009-07-21 | Choongwae Pharma Corporation | Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation |
-
2006
- 2006-11-08 WO PCT/US2006/043859 patent/WO2007056593A2/en not_active Ceased
- 2006-11-08 AU AU2006311433A patent/AU2006311433B2/en active Active
- 2006-11-08 KR KR1020087013755A patent/KR101486490B1/ko active Active
- 2006-11-08 EP EP06844324.1A patent/EP1957516B1/en active Active
- 2006-11-08 JP JP2008540227A patent/JP5536336B2/ja active Active
- 2006-11-08 CA CA2629136A patent/CA2629136C/en active Active
- 2006-11-08 ES ES06844324T patent/ES2570994T3/es active Active
- 2006-11-08 US US11/594,576 patent/US20070129353A1/en not_active Abandoned
-
2009
- 2009-11-11 US US12/616,712 patent/US8293743B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515890A5 (enExample) | ||
| AU2019414550B2 (en) | FAK inhibitor and drug combination thereof | |
| KR102091893B1 (ko) | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 | |
| Solak et al. | Synthesis and antituberculosis activity of 2-(aryl/alkylamino)-5-(4-aminophenyl)-1, 3, 4-thiadiazoles and their Schiff bases | |
| AU2017335242C1 (en) | Pyridine compound | |
| EP3528803A1 (en) | Compounds and methods to sensitize cancer cells to cisplatin | |
| TW201811793A (zh) | 吡咯並苯並二氮呯類和彼等之共軛物類 | |
| HRP20141120T1 (hr) | Furazanobenzimidazoli kao predlijekovi za lijeäśenje neoplastiäśnih ili autoimunih bolesti | |
| JP2008535902A5 (enExample) | ||
| CA2412968A1 (en) | Substituted pyridines as selective cyclooxygenase-2 inhibitors | |
| JP2011506402A5 (enExample) | ||
| JP2009534408A5 (enExample) | ||
| HRP20100166T1 (hr) | Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze | |
| RU2010142396A (ru) | Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1-н-бензимидазол-2-ил] хинолин-2(1н)она | |
| US12371417B2 (en) | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | |
| WO2020029980A1 (en) | Smad3 inhibitors | |
| EA200800516A1 (ru) | Производные n-фенил-2-пиримидинамина и процесс их получения | |
| JP2008508287A5 (enExample) | ||
| AU2007264665A1 (en) | Potentiator of radiation therapy | |
| WO2017198194A1 (zh) | 一种硼酸和硼酸酯类化合物及其应用 | |
| CA2602199A1 (en) | Heteroaryl urea derivatives useful for inhibiting chk1 | |
| KR20140044790A (ko) | 피페라진디온 화합물 | |
| JP2008179567A (ja) | ピラジン誘導体を有効成分とする抗がん剤 | |
| JP2014530813A (ja) | フェニル−グアニジン誘導体 | |
| Sun et al. | Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1, 3, 5-triazine family |